Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111536 · ClinicalTrials.gov registry record · Phase 1
Developing Oral LT3 Therapy for Heart Failure - HFpEF
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04111536: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT04111536 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04111536, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction (HFpEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-over study with a two-week washout period between treatments.
Interventions
- OTHER Placebo
- DRUG liothyronine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-03-08 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111536
The ClinicalTrials.gov registry entry for NCT04111536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04111536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04111536 about?
NCT04111536 is a clinical study titled "Developing Oral LT3 Therapy for Heart Failure - HFpEF". Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction (HFpEF) and low triiodothyronine (T3) syndrome by conducting a randomized, double-blind, placebo-controlled cross-o...
What is the current status of trial NCT04111536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-03-08. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT04111536?
The interventions under investigation include: Placebo (OTHER), liothyronine (DRUG).
Who is sponsoring clinical trial NCT04111536?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.